Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Preclinical feasibility analysis for Phase I study using adoptive iNKT cell transfer to prevent GVHD

View Full Paper
Ask AI
Bookmark
Share

Authors

KBKelsey BuskenMMMelissa Mavers

Discussion

Loading...

Member takes

Overview

Preclinical analysis demonstrates cytokine production in iNKT cells for GVHD prevention, suggesting a new treatment protocol.

Key Points

  • Clinical trial suggests iNKT cell transfer may prevent graft versus host disease effectively, supporting further evaluation.
  • Key metric shows maintaining IL-4 production in iNKT cells after cryopreservation enhances clinical application potential.
  • Observational analysis employing PBMC enrichment techniques to enhance iNKT cell purity and functionality for HSCT.
  • Supports the development of standards for iNKT cell therapy production with Good Manufacturing Practice guidelines.

Cite This Study

Busken et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db41https://doi.org/10.1182/blood-2025-5967
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Generation of iNKT cells with hematopoiesis-promoting properties from human iPSCs2025
  2. 2Donor Variability and Seeding Density Shape NK-Cell Proliferation and Surface Receptor Expression: Insights from an Integrated Phenotypic and Genetic Analysis2025
  3. 3Experience in developing and scaling a protocol for NK lymphocyte enriched cellular product manufacturing for clinical application2025
  4. 4Phenotyping of ex vivo expanded NK cells reveals unique transcriptomic and epigenetic signatures2025
  5. 5More than IL-2: Optimizing feeder-free NK cell function through cytokine synergy2025